Bimatoprost, Obtains CN DS License.

Congratulations!
Everlight Pharmaceutical Product, Bimatoprost, Obtains CN DS License

“On January 26, 2025, our Pharmaceutical product, Bimatoprost, a drug substance(DS)/API for glaucoma, obtained DS/API certification in mainland China, making it the second non-Chinese manufacturer to receive CDE certification of China. We will work closely with our Chinese distributor to actively increase market share and boost revenue in the future.”

Glaucoma is a chronic and progressive optic neuropathy characterized by optic nerve atrophy and gradual visual field loss, primarily caused by abnormal intraocular pressure (IOP). The damage caused by glaucoma is irreversible. The goal of glaucoma treatment is to lower IOP or maintain it within a stable range to prevent further deterioration of the optic nerve.

According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness worldwide, with the proportion of affected individuals increasing with age. In recent years, the incidence of glaucoma has been gradually increasing, with a trend towards a younger age of onset. This is attributed to the rising proportion of people with high myopia and advancements in diagnostic technology. China has the largest number of glaucoma patients globally. Epidemiological data suggests that in 2020, the number of glaucoma patients in China reached 21.8 million, with an estimated 5.67 million people blinded by the disease.¹

According to the 2020 European Glaucoma Society: TERMINOLOGY and GUIDELINES for GLAUCOMA and the Chinese Glaucoma Guidelines 2020, prostaglandins are unanimously recommended as the first-line treatment for primary open-angle glaucoma ^2,3 and bimatoprost is one of the most commonly used prescription prostaglandin eye drops in China for the treatment of this disease.